Oxaliplatin: a review of approved uses

Bibliography

• Ferlay J, Shin HR, Bray F. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;13(12):2893-2917
   Google Scholar
• Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-81
   PubMed Web of Science ®Google Scholar
• La Vecchia C, Bosetti C, Lucchini F, Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 2010;21:1323-60
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Lang I, Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-19
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Schmiegel W, Pox C, Arnold D. Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases. Dtsch Arztebl Int 2009;106:843-8
   PubMedGoogle Scholar
• Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010;21(Suppl 5):v93-7
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Navarro M, Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16
   PubMed Web of Science ®Google Scholar
• Kuebler JP, Wieand HS, O'Connell MJ, Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:2198-204
   PubMed Web of Science ®Google Scholar
• Haller DG, Tabernero J, Maroun J, Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer. J Clin Oncol 2011;29:1465-71
   PubMed Web of Science ®Google Scholar
• Cunningham D, Atkin W, Lenz HJ, Colorectal cancer. Lancet 2010;375:1030-47
   PubMed Web of Science ®Google Scholar
• Ehrsson H, Wallin I, Yachnin J. Pharmacokinetics of oxaliplatin in humans. Med Oncol 2002;19:261-5
   PubMed Web of Science ®Google Scholar
• Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 2011;18:18-25
   PubMed Web of Science ®Google Scholar
• Zwelling LA, Anderson T, Kohn KW. DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res 1979;39:365-9
   PubMed Web of Science ®Google Scholar
• Faivre S, Chan D, Salinas R. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 2003;66:225-37
   PubMed Web of Science ®Google Scholar
• Woynarowski JM, Faivre S, Herzig MC, Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000;58:920-7
   PubMed Web of Science ®Google Scholar
• Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci 2002;59:1914-27
   PubMed Web of Science ®Google Scholar
• Fischel JL, Formento P, Ciccolini J, Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity. Br J Cancer 2002;86:1162-8
   PubMed Web of Science ®Google Scholar
• Todd RC, Lippard SJ. Inhibition of transcription by platinum antitumor compounds. Metallomics 2009;1:280-91
   PubMed Web of Science ®Google Scholar
• Tesniere A, Schlemmer F, Boige V, Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010;29:482-91
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Oza AM, Bigelow RH, Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-69
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF, A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30
   PubMed Web of Science ®Google Scholar
• Patel M, Agarwal R, Ardalan B. Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines. J Cancer Res Clin Oncol 2004;130:453-9
   PubMedGoogle Scholar
• Raymond E, Buquet-Fagot C, Djelloul S, Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997;8:876-85
   PubMed Web of Science ®Google Scholar
• Joel SP, Papamichael D, Richards F, Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. Clin Pharmacol Ther 2004;76:45-54
   PubMedGoogle Scholar
• Allegra CJ, Yothers G, O'Connell MJ, Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29:11-16
   PubMed Web of Science ®Google Scholar
• De Gramont A, Van Cutsem E. AVANT: results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. J Clin Oncol 2011;29: abstract 362
   Google Scholar
• Alberts SR, Sargent D. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG intergroup phase III trial N0147. J Clin Oncol 2010;28:CRA3507
   Google Scholar
• Morelli MP, Cascone T, Troiani T, Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 2005;16(Suppl 4):iv61-8
   PubMedGoogle Scholar
• Balin-Gauthier D, Delord JP, Pillaire MJ, Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer 2008;98:120-8
   PubMed Web of Science ®Google Scholar
• Prewett M, Deevi DS, Bassi R, Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. Clin Cancer Res 2007;13:7432-40
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Hartmann JT, Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22:1535-46
   PubMed Web of Science ®Google Scholar
• Tveit K, Guren T. Randomized phase III study of 5-Fluorouracil/folinate/oxaliplatin given continously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314). Ann Oncol 2010;21:LBA 20
   Google Scholar
• Maughan TS, Adams RA, Smith CG, Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-14
   PubMed Web of Science ®Google Scholar
• Rivera F, Gravalos C. Cetuximab plus capecitabine as first-line treatment for elderly patients (pts) with advanced colorectal cancer (mCRC). Final analysis of activity and survival according to KRAS status - the TTD-06-01 Spanish Cooperative Group trial. Eur J Cancer 2009;7:215
   Google Scholar
• Goldberg RM, Sargent DJ. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG intergroup phase III trial N0147. J Clin Oncol 2010;28: abstract 3508
   Google Scholar
• Glynne-Jones R, Mawdsley S, Harrison M. Antiepidermal growth factor receptor radiosensitizers in rectal cancer. Anticancer Drugs 2011;22:330-40
   PubMedGoogle Scholar
• Graham MA, Lockwood GF, Greenslade D. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000;6:1205-18
   PubMed Web of Science ®Google Scholar
• Morrison JG, White P, McDougall S, Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. J Pharm Biomed Anal 2000;24:1-10
   PubMed Web of Science ®Google Scholar
• Takimoto CH, Graham MA, Lockwood G, Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 2007;13:4832-9
   PubMed Web of Science ®Google Scholar
• Synold TW, Takimoto CH, Doroshow JH, Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 2007;13:3660-6
   PubMedGoogle Scholar
• Caussanel JP, Levi F, Brienza S, Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990;82:1046-50
   PubMed Web of Science ®Google Scholar
• Extra JM, Espie M, Calvo F. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990;25:299-303
   PubMed Web of Science ®Google Scholar
• Mathe G, Kidani Y, Triana K, A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). Biomed Pharmacother 1986;40:372-6
   PubMed Web of Science ®Google Scholar
• Becouarn Y, Ychou M, Ducreux M, Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998;16:2739-44
   PubMed Web of Science ®Google Scholar
• Diaz-Rubio E, Sastre J, Zaniboni A, Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998;9:105-8
   PubMed Web of Science ®Google Scholar
• Machover D, Diaz-Rubio E, de Gramont A, Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-8
   PubMed Web of Science ®Google Scholar
• Levi F, Perpoint B, Garufi C, Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993;29A:1280-4
   PubMed Web of Science ®Google Scholar
• Levi F, Zidani R, Brienza S, A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer 1999;85:2532-40
   PubMed Web of Science ®Google Scholar
• Levi F, Misset JL, Brienza S, A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992;69:893-900
   PubMed Web of Science ®Google Scholar
• Maindrault-Goebel F, de Gramont A, Louvet C, Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 2000;11:1477-83
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L, Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51
   PubMed Web of Science ®Google Scholar
• Haller D, Cassidy J. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): No impact of age on disease-free survival (DFS). Gastrointestin Cancer Symp 2010; abstract 284
   Google Scholar
• Yothers G, Allegra C. The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer. J Clin Oncol 2011;29: abstract 3507
   Google Scholar
• Schmoll HJ, Cartwright T, Tabernero J, Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007;25:102-9
   PubMed Web of Science ®Google Scholar
• Labianca R, Nordlinger B, Beretta GD. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v70-7
   PubMed Web of Science ®Google Scholar
• Aschele C, Cionini L, Lonardi S, Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011;29:2773-80
   PubMed Web of Science ®Google Scholar
• Roedel C, Becker H. Pre operative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: first results of the German CAO/ARO/AIO-04 randomized phase III trial. J Clin Oncol 2011;29: abstract LBA3505
   Google Scholar
• Roh MS, Yothers GA. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 2011;29: abstract 3503
   Google Scholar
• Gerard JP, Azria D, Gourgou-Bourgade S, Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010;28:1638-44
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Perpoint B, Zidani R, Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47
   PubMed Web of Science ®Google Scholar
• De Gramont A, Krulik M, Cady J, High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988;24:1499-503
   PubMedGoogle Scholar
• Haller DG, Rothenberg ML, Wong AO, Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol 2008;26:4544-50
   PubMed Web of Science ®Google Scholar
• Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International organization for cancer chronotherapy. Lancet 1997;350:681-6
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Bjarnason G, Garufi C, Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006;24:3562-9
   PubMed Web of Science ®Google Scholar
• Cassidy J, Clarke S, Diaz-Rubio E, Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26:2006-12
   PubMed Web of Science ®Google Scholar
• Porschen R, Arkenau HT, Kubicka S, Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007;25:4217-23
   PubMed Web of Science ®Google Scholar
• Diaz-Rubio E, Tabernero J, Gomez-Espana A, Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007;25:4224-30
   PubMed Web of Science ®Google Scholar
• Ducreux M, Bennouna J, Hebbar M, Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 2011;128:682-90
   PubMed Web of Science ®Google Scholar
• Arkenau HT, Arnold D, Cassidy J, Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008;26:5910-17
   PubMed Web of Science ®Google Scholar
• Falcone A, Ricci S, Brunetti I, Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-6
   PubMed Web of Science ®Google Scholar
• Souglakos J, Androulakis N, Syrigos K, FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006;94:798-805
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S. Final results from PRIME:. randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC). J Clin Oncol 2011;29: abstract 3510
   PubMedGoogle Scholar
• Bokemeyer C, Bondarenko I, Makhson A, Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71
   PubMed Web of Science ®Google Scholar
• Adams RA, Meade AM, Seymour MT, Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011;12:642-53
   PubMed Web of Science ®Google Scholar
• Chibaudel B, Maindrault-Goebel F, Lledo G, Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009;27:5727-33
   PubMed Web of Science ®Google Scholar
• Tournigand C, Cervantes A, Figer A, OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer–a GERCOR study. J Clin Oncol 2006;24:394-400
   PubMed Web of Science ®Google Scholar
• Grothey A. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. J Clin Oncol 2008;26: abstract 4010
   Google Scholar
• Weber SM, Jarnagin WR, DeMatteo RP, Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol 2000;7:643-50
   PubMedGoogle Scholar
• Choti MA, Sitzmann JV, Tiburi MF, Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759-66
   PubMed Web of Science ®Google Scholar
• Tomlinson JS, Jarnagin WR, DeMatteo RP, Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007;25:4575-80
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-16
   PubMed Web of Science ®Google Scholar
• Gruenberger B, Tamandl D, Schueller J, Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008;26:1830-5
   PubMed Web of Science ®Google Scholar
• Wong R, Cunningham D, Barbachano Y, A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011;22:2042-8
   PubMed Web of Science ®Google Scholar
• Voest EE, Snoeren N. A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer. J Clin Oncol 2011;29: abstract 3565
   Google Scholar
• Goldberg RM, Tabah-Fisch I, Bleiberg H, Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085-91
   PubMed Web of Science ®Google Scholar
• Jackson McCleary NA, Meyerhardt J. Impact of older age on the efficacy of newer adjuvant therapies in > 12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT Database. J Clin Oncol 2009;27: abstract 4010
   Google Scholar
• Haller D, Cassidy J. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): Impact of age on disease-free survival (DFS). J Clin Oncol 2010;28: abstract 3521
   Google Scholar
• Yothers G, O'Connell MJ, Allegra CJ, Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011;29:3768-74
   PubMed Web of Science ®Google Scholar
• Seymour MT, Thompson LC, Wasan HS, Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 2011;377:1749-59
   PubMed Web of Science ®Google Scholar
• Berretta M, Lleshi A, Cappellani A, Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection. Curr HIV Res 2010;8:218-22
   PubMedGoogle Scholar
• Koutras AK, Makatsoris T, Paliogianni F, Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology 2004;67:179-82
   PubMed Web of Science ®Google Scholar
• Grolleau F, Gamelin L, Boisdron-Celle M, A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001;85:2293-7
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Tredici G, Petruccioli MG, Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001;37:2457-63
   PubMed Web of Science ®Google Scholar
• Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res 2006;12:4481-4
   PubMed Web of Science ®Google Scholar
• Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2011;2:CD005228
   PubMed Web of Science ®Google Scholar
• Grothey A, Nikcevich DA, Sloan JA, Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 2011;29:421-7
   PubMed Web of Science ®Google Scholar
• Gamelin L, Boisdron-Celle M, Morel A, Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008;26:1188-9; author reply 9-90
   PubMed Web of Science ®Google Scholar
• Ibrahim A, Hirschfeld S, Cohen MH. FDA drug approval summaries: oxaliplatin. Oncologist 2004;9:8-12
   PubMed Web of Science ®Google Scholar
• Raez LE, Kobina S, Santos ES. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer. Clin Lung Cancer 2010;11:18-24
   Google Scholar
• Montagnani F, Turrisi G, Marinozzi C. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2011;14:50-5
   PubMed Web of Science ®Google Scholar
• Wolmark N, Wieand S. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07. J Clin Oncol 2008;26: abstract LBA4005
   Google Scholar